The company's lead drug candidate, T3D-959, is currently in Phase 2 clinical trials and is designed to improve brain glucose energy and lipid metabolism, addressing structural and stress-related abnormalities in the brain. Unlike other therapies targeting specific abnormalities, T3D-959 acts in a multidimensional manner by regulating various genes involved in Alzheimer's disease pathologies. Founded in 2013 and based in Durham, North Carolina, T3D Therapeutics aims to provide a once-a-day oral medicine that can improve memory, motor function, and cognition in Alzheimer's patients.